Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevrometostat Plus Enzalutamide in mCRPC (MOMENT)
NCT07592910Phase 2Not yet recruiting
- Sponsor
- Prostate Cancer Clinical Trials Consortium
- Start
- Aug 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mevrometostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Prostate Cancer Clinical Trials Consortium. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mevrometostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07592910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592910.